| Acute Coronary Syndrome |
EKSTROM, NCT06342609: Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease |
|
|
| Active, not recruiting | 4 | 84 | US | Colchicine 0.5 MG, Mitigare, Colcrys | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Coronary Artery Disease | 09/24 | 09/24 | | |
ACCP, NCT05573958: To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome |
|
|
| Not yet recruiting | 4 | 90 | NA | Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Clopidogrel tablet, Plavix, Aspirin tablet, Acetylsalicylic acid | Sarmad Zahoor, University of Managemant and Technology, Pakistan, Mayo Hospital Lahore | Acute Coronary Syndrome | 03/23 | 07/23 | | |
ChiCTR2200057772: Short-term evaluation of modified, low-dose PCSK9 inhibitors combined with statins in the treatment of acute coronary syndrome dyslipidemia in Chinese |
|
|
| Not yet recruiting | 4 | 100 | | receive medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn) ;receive medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)+once a month, subcutaneous injection of 1 injection of PCSK9 inhibitor each time ;receive medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)+twice a month, subcutaneous injection of 1 injection of PCSK9 inhibitor each time | The First Affiliated Hospital of Nanjing Medical University; Jiangsu Provincial People's Hospital, Self-funded | acute coronary syndrome | | | | |
NCT05298475: Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome |
|
|
| Not yet recruiting | 4 | 100 | RoW | Statin, PCSK9 inhibitor | The First Affiliated Hospital with Nanjing Medical University | Acute Coronary Syndrome | 04/23 | 04/24 | | |
ChiCTR2100054620: Study on the Safety and Effectiveness of Guanxinning Tablets in Intensive Therapy for Patients with Acute Coronary Syndrome |
|
|
| Not yet recruiting | 4 | 114 | | Conventional treatment ;The loading treatment group was given intensive treatment with Guanxinning Tablets | Hangzhou First People's Hospital; Hangzhou First People's Hospital, Hangzhou Biomedicine and Health Industry Development Support Technology Special Construction | Acute Coronary Syndrome | | | | |
TICO, NCT02494895: Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome ( Study) |
|
|
| Recruiting | 4 | 3056 | RoW | Ticagrelor monotherapy, Brilinta®, Ticagrelor with Aspirin DAPT(dual antiplatelet treatment) | Yonsei University | Acute Coronary Syndrome | 05/23 | 05/23 | | |
ChiCTR2200057508: Effect of PCSK9 monoclonal antibody on serum lipids and cardiovascular events in patients with ACS before and after PCI: a single-center, prospective, randomized controlled trial |
|
|
| Not yet recruiting | 4 | 240 | | Irolumab 140mg was administered 1-3 days before PCI, followed by irolumab 140mg/2w for 6 months ;Irolumab 140mg was administered 2 weeks after PCI, followed by irolumab 140mg/2w for 6 months ;Use the maximum tolerated dose of statins | Tangdu Hospital of Air Force Millitary Medical University; Tangdu Hospital of Air Force Millitary Medical University, Tangdu Hospital 2021 Clinical Research Project | Acute Coronary Syndrome | | | | |
| Ongoing | 4 | 75 | Europe | Tablet, Plavix | Sint Antonius Ziekenhuis, St. Antonius Ziekenhuis | Non-ST elevation acute coronary syndrome (coronary artery disease) Non-ST segment elevatie acuut coronair syndroom (coronairlijden), Coronary artery disease Coronairlijden, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2023-000123-37: Efficacy of CONservative versus invasive therapy in acute Coronary syndrome with plaque Erosion PhenoType - the CONCEPT-ACS trial Efficacia della terapia conservativa rispetto alla terapia invasiva nella sindrome coronarica acuta con fenotipo da erosione di placca – il CONCEPT-ACS trial |
|
|
| Not yet recruiting | 4 | 400 | Europe | Brilique, EPSOCLAR, Colchicina, CARDIOASPIRIN, NA, Orodispersible tablet, Solution for infusion, Tablet, Gastro-resistant tablet | FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Ministero della Salute | patients affected by acute coronary syndrome with plaque erosion phenotype sindrome coronarica acuta con fenotipo di erosione della placca, patients affected by acute coronary syndrome with plaque erosion phenotype sindrome coronarica acuta con fenotipo di erosione della placca, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Recruiting | 4 | 320 | RoW | Rivaroxaban, Warfarin | National Institute of Cardiovascular Diseases, Pakistan | Acute Coronary Syndrome, Left Ventricular Thrombus | 12/23 | 01/24 | | |
NCT04090281: Implementing Precision Medicine Approaches to Guide Anti-platelet Selection |
|
|
| Active, not recruiting | 4 | 200 | US | CYP2C19 genotyping, platelet reactivity phenotyping | University of Southern California | Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation MI, Unstable Angina (UA) | 05/23 | 11/23 | | |
TIGER-diabetes, NCT04307511: A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients |
|
|
| Recruiting | 4 | 40 | RoW | Ticagrelor, Aspirin | Shanghai Tong Ren Hospital | Acute Coronary Syndrome Patients With Diabetes After PCI | 04/24 | 05/24 | | |
ChiCTR2100054242: Clinical study on coronary intervention combined with guanxinning tablets in treatment of acute coronary syndrome |
|
|
| Recruiting | 4 | 60 | | Antiplatelet drugs, lipid-lowering drugs, β-blockers, ACEIs (Angiotesion Converting Enzyme Inhibito), etc. ;Conventional treatment + Guanxinning Tablets | Hangzhou Red Cross Hospital; Hangzhou Red Cross Hospital, Hangzhou Municipal Health Commission Project | Acute coronary syndrome | | | | |
| Recruiting | 4 | 634 | Europe | Clopidogrel, Previous treatment | Fundación EPIC | Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention | 06/23 | 06/23 | | |
NCT05263778: Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study |
|
|
| Not yet recruiting | 4 | 500 | US | Bempedoic Acid / Ezetimibe Oral Tablet, Nexlizet, Placebo | Kaiser Permanente, Esperion Therapeutics, Inc. | Cardiovascular Diseases, NSTEMI, STEMI | 06/23 | 12/23 | | |
ChiCTR2100052583: Clinical study on protection of endothelial function in patients with acute coronary syndrome by Suxiao Jiuxin Wan |
|
|
| Recruiting | 4 | 120 | | Suxiao Jiuxin Wan ;Suxiao Jiuxin Wan placebo | Guangdong Hospital of Traditional Chinese Medicine; Guangdong Hospital of Traditional Chinese Medicine, Sponsored by Tianjin Zhongxin Pharmaceutical Co., Ltd | Acute coronary syndrome | | | | |
NCT06053983: Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome |
|
|
| Completed | 4 | 126 | RoW | Turbox CRP kit, rosuvastatin 20 mg,, atorvastatin 40 mg | Rawalpindi Medical College | Mi Q Wave | 08/23 | 08/23 | | |
| Completed | 4 | 128 | RoW | Colchicine, Placebo | Wuhan Union Hospital, China | Acute Coronary Syndrome | 08/23 | 10/23 | | |
ChiCTR2100053723: Clinical Trial of Suxiao Jiuxin Pill to Protect Endothelial Function in Patients With Acute Coronary Syndrome |
|
|
| Recruiting | 4 | 120 | | Secondary Prevention of Coronary heart Disease + Suxiaojiuxin Pills (5 tablets, P.O. TID) ;Secondary prevention of coronary heart disease + placebo (5 tablets, P.O. TID) | Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial Hospital of Traditional Chinese Medicine, The Sixth Traditional Chinese Medicine Factory of Tianjin Zhongxin Pharmaceutical Group Co., Ltd. | Acute coronary syndrome | | | | |
NCT04814121: Suxiao Jiuxin Pills in Microvascular Obstruction in Patients With Acute Coronary Syndrome |
|
|
| Not yet recruiting | 4 | 198 | NA | Suxiao Jiuxin Pills, The placebo of Suxiao Jiuxin Pills | Guangzhou University of Traditional Chinese Medicine | Acute Coronary Syndrome | 09/23 | 09/23 | | |
NCT06321094: Effect of Vericiguat on Endpoint Events in Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45% |
|
|
| Recruiting | 4 | 100 | RoW | Vericiguat | The First Affiliated Hospital with Nanjing Medical University | Acute Coronary Syndrome, Heart Failure With Reduced Ejection Fraction | 10/25 | 12/25 | | |
NCT06114641: Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation Acute Coronary Syndrome (NSTEACS) Patients: a Multicenter, Non-randomized, Open-label, Non-inferiority Trial |
|
|
| Recruiting | 4 | 220 | RoW | Enoxaparin sodium injection, Originator Enoxaparin | PT Bio Farma | Safety Issues, Effect of Drug | 11/23 | 12/23 | | |
ChiCTR1900025842: A randomized, double-blind, placebo parallel controlled, multi-center clinical study of Tongxinluo capsule in the treatment of acute coronary syndrome with atherosclerotic plaque |
|
|
| Completed | 4 | 220 | | Standardized treatment of acute coronary syndrome + Tongxinluo capsule 4 capsules / time, 3 times / day, oral ;Standardized treatment of acute coronary syndrome + Tongxinluo capsule placebo 4 capsules / time, 3 times / day, oral | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, National Key Technologies R&D Program, Modernization of Traditional Chinese Medicine of Ministry of Science and Technogy of the People's Republic of China (Project No. 2017YFC1700500) | Acute coronary syndrome | | | | |
| Active, not recruiting | 4 | 6002 | Japan | No aspirin, 1-month DAPT | Kyoto University, Graduate School of Medicine | Acute Coronary Syndrome | 12/23 | 12/25 | | |
ChiCTR2100053739: A randomised controlled study of the effect of statins on lipoprotein(a) and cardiovascular events after PCI in patients with ACS |
|
|
| Not yet recruiting | 4 | 600 | | Intensive treatment group ;Normal dose | The First Affiliated Hospital of Xinjiang Medical University; The First Affiliated Hospital of Xinjiang Medical University, self-funded | Acute coronary syndrome | | | | |
ChiCTR2200055718: Effects of PCSK9 inhibitor therapy on fractional flow reserve in coronary borderline lesions |
|
|
| Recruiting | 4 | 170 | | On the basis of conventional statin therapy, use Repatha subcutaneous injection to treat 1 vial of Q2W ;Atorvastatin 20mg/day or rosuvastatin 10mg/day | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Suzhou Industrial Park Xinxin Cardiovascular Health Foundation | Coronary atherosclerosis | | | | |
| Recruiting | 4 | 48 | RoW | Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel, Monotherapy: Ticagrelor alone OR Prasugrel alone | Hospital Israelita Albert Einstein | Acute Coronary Syndrome | 02/24 | 03/24 | | |
ADONIS-PCI, NCT04695106: Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI |
|
|
| Recruiting | 4 | 2230 | Europe | Ticagrelor, Brilique, Dabigatran Etexilate, Pradaxa, Aspirin, Clopidogrel | Medical University of Gdansk, Medical University of Warsaw, Nicolaus Copernicus University, Institute of Cardiology, Warsaw, Poland, Military Institute of Medicine, Poland, Bielanski Hospital, Medical University of Silesia, Poznan University of Medical Sciences, University of Opole, Poland, Medical University of Łódź, Voivodeship Hospital, Kielce, Poland, Voivode Specialist Hospital in Olsztyn, Poland, Medical University of Lublin, Pomeranian Medical University Szczecin, Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland | Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome, Percutaneous Coronary Interventions | 03/24 | 03/26 | | |
NCT06283888: CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention |
|
|
| Recruiting | 4 | 1200 | RoW | CYP2C19 Genotype Guided DAPT, Guided DAPT, Conventional DAPT, Unguided DAPT | Zunyi Medical College | ACS - Acute Coronary Syndrome, CYP2C19 Polymorphism | 04/28 | 12/28 | | |
| Recruiting | 4 | 140 | Europe | A computerized tomography (CT) coronary angiogram, Vicorder (Skidmore medical, UK), Blood tests for inflammation and oxidative stress markers | Swansea Bay University Health Board | Diabetes Mellitus, Acute Coronary Syndrome, Coronary Artery Disease | 04/24 | 08/24 | | |
NCT05401240: Using Cardiopulmonary Exercise Test as an Incentive to Outpatient Cardiac Rehabilitation for Acute Coronary Syndrome Survivors. |
|
|
| Not yet recruiting | 4 | 200 | RoW | information reveal | Taichung Veterans General Hospital | Acute Coronary Syndrome | 05/24 | 12/24 | | |
| Active, not recruiting | 4 | 2488 | Europe | Novel strategy Aspirin, Conventional strategy Aspirin | Assistance Publique - Hôpitaux de Paris, Bayer | Diabetes Mellitus, Acute Coronary Syndrome, Coronary Artery Disease, Obesity | 06/24 | 06/24 | | |
NCT04307485: A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients |
|
|
| Recruiting | 4 | 40 | RoW | Ticagrelor | Shanghai Tong Ren Hospital | Senior Acute Coronary Syndrome Patients After PCI | 06/24 | 07/24 | | |
CAPRICI, NCT06421363: Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart Disease |
|
|
| Not yet recruiting | 4 | 50 | Europe | Inclisiran | Jose Seijas Amigo | Ischemic Heart Disease, Acute Coronary Syndrome | 06/25 | 08/27 | | |
NCT06429345: Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients. |
|
|
| Recruiting | 4 | 250 | RoW | Coenzyme Q10 100 Milligrams Oral Capsule, Coenzyme Q10, Placebo | Ain Shams University | Contrast-induced Nephropathy | 10/24 | 11/24 | | |
OPTION2, NCT06451198: IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome |
|
|
| Not yet recruiting | 4 | 2846 | NA | Indobufen, Aspirin, Ticagrelor | Shanghai Zhongshan Hospital | Coronary Artery Disease | 05/26 | 05/27 | | |
OPTIEP, ChiCTR2200062478: Optimal anti-platelet therapy in elderly patients with acute coronary syndromes undergoing percutaneous coronary intervention |
|
|
| Not yet recruiting | 4 | 159 | | Ticagrelor 90 mg bid + aspirin 100 mg qd was maintained until 1 month after PCI, and after 1 month, it was changed to ticagrelor 60 mg bid + aspirin 100 mg qd until 1 year after PCI. ;Ticagrelor 90 mg bid + aspirin 100 mg qd was maintained until 1 year after PCI. ;Clopidogrel 75mg qd + aspirin 100mg qd maintained for 1 year after PCI. | Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Central Health Research Project | Acute Coronary Syndrome | | | | |
NCT06409117: 3rd Generation Resorbable Magnesium Scaffolds vs Biodegradable Polymer Stents in NSTE/ACS |
|
|
| Not yet recruiting | 4 | 220 | Europe | Percutaneous coronary intervention | Konstantinos Toutouzas, Centre Hospitalier Universitaire Saint Pierre, Université Catholique de Louvain, University Hospital of Leuven Leuven, University of Patras, Ippokrateio General Hospital of Thessaloniki | Acute Coronary Syndrome, Coronary Artery Disease | 12/27 | 12/27 | | |
ChiCTR2200060740: A randomized controlled study comparing the perioperative efficacy and safety of fondaparinux sodium with low molecular weight heparin sodium before simple coronary artery bypass grafting in non ST-segment elevation acute coronary syndrome |
|
|
| Not yet recruiting | 4 | 146 | | Subcutaneous injection of fondaparinux sodium ;Subcutaneous injection of low molecular weight heparin sodium | Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Hengrui pharmaceutical joint fund project in 2021 | non ST-segment elevation acute coronary syndrome | | | | |
SCA FA, NCT04276155: Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia |
|
|
| Recruiting | 4 | 500 | Europe | non-systematic prescription of anticoagulant therapy | Centre Hospitalier de PAU | Atrial Fibrillation, Myocardial Infarction | 12/24 | 12/24 | | |
NCT04719221: Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome |
|
|
| Recruiting | 4 | 60 | RoW | Evolocumab, Repatha, NIRS IVUS | Korea University Anam Hospital | Clinical Trial, Acute Coronary Syndrome | 12/24 | 12/24 | | |
ChiCTR2200064363: Bivalirudin infusion at standard or low regimen during elective percutaneous coronary intervention in patients with acute coronary syndrome: a prospective, single-center, randomized controlled study |
|
|
| Recruiting | 4 | 2510 | | Bivalirudin infusion at standard regimen ;Bivalirudin infusion at low (standard of 80 percent) regimen | The PLA Northern Theater Command General Hospital ; General Hospital of Northern Theater Command, None | acute coronary syndrome | | | | |
TOP-CABG, NCT05380063: Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting |
|
|
| Recruiting | 4 | 2300 | RoW | De-escalated Dual Antiplatelet Therapy, De-escalation, Dual Antiplatelet Therapy | China National Center for Cardiovascular Diseases | Coronary Artery Disease, Coronary Artery Bypass Grafting, Dual Antiplatelet Therapy, Bleeding, Myocardial Infarction, Myocardial Ischemia, Angina Pectoris | 12/24 | 12/25 | | |
EPIDAURUS, NCT04981041: Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI |
|
|
| Recruiting | 4 | 2334 | Europe | Prasugrel or Ticagrelor, Clopidogrel | Ludwig-Maximilians - University of Munich | Acute Coronary Syndrome, Atrial Fibrillation | 12/24 | 06/25 | | |
NCT03234114: Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4) |
|
|
| Recruiting | 4 | 3746 | RoW | Triple antithrombotic therapy, TAT, Dual antithrombotc therapy-1, DAT-1, Dual antithrombotc therapy-2, DAT-2 | The First Affiliated Hospital with Nanjing Medical University | Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF) | 12/24 | 12/24 | | |
TIGER, NCT04255602: A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients |
|
|
| Recruiting | 4 | 2120 | RoW | Ticagrelor 60mg, Ticagrelor 90mg | Shanghai Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Fudan University | Acute Coronary Syndrome, Coronary Stent Implantation | 12/24 | 12/24 | | |
SWITCH, NCT05183178: Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome |
|
|
| Recruiting | 4 | 16000 | Europe | Prasugrel 10 mg p.o, Ticagrelor 90 mg | Vastra Gotaland Region, Region Skane, Region Halland, Region Gävleborg, Region Örebro County, Region Västerbotten, Jämtland County Council, Sweden | Acute Coronary Syndrome | 01/25 | 12/25 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
| Recruiting | 4 | 2200 | Europe, RoW | Ticagrelor 90mg twice daily and ASA 75-100 mg daily, ASA 75-160 mg daily | Vastra Gotaland Region, Gothia Forum - Center for Clinical Trial, Uppsala University | Acute Coronary Syndrome | 06/25 | 06/31 | | |
| Recruiting | 4 | 2500 | Europe, RoW | Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care | CoreAalst BV, Insight Lifetech Co., Ltd. | Coronary Artery Disease, Acute Coronary Syndrome | 06/25 | 06/29 | | |
LEGACY, NCT05125276: Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients |
|
|
| Recruiting | 4 | 3090 | Europe | No aspirin, Aspirin | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Non ST Segment Elevation Acute Coronary Syndrome | 07/25 | 07/25 | | |
| Recruiting | 4 | 120 | US | Tirzepatide, Mounjaro, Placebo | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Eli Lilly and Company | Type II Diabetes, Atherosclerosis | 12/25 | 05/26 | | |
C-STAR, NCT05661552: Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI |
|
|
| Recruiting | 4 | 102 | RoW | Evolocumab 140 MG/ML, REPATHA® (Amgen Inc, Thousand Oaks, California, USA), Rosuvastatin 5mg, Ezetimibe 10mg | Yonsei University, Daewoong Pharmaceutical Co. LTD. | Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia | 11/25 | 11/25 | | |
MATE, NCT04937699: Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention |
|
|
| Recruiting | 4 | 2690 | RoW | Standard-DAPT of Ticagrelor plus aspirin, DAPT, Sequential monotherapy of Ticagrelor and clopidogrel, SAPT | Second Affiliated Hospital, School of Medicine, Zhejiang University | Acute Coronary Syndrome, Percutaneous Coronary Intervention | 12/25 | 12/25 | | |
PROACT 2, NCT05850091: Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine |
|
|
| Recruiting | 4 | 200 | US | Rosuvastatin, Colchicine, Placebo | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Coronary Artery Disease | 07/26 | 07/27 | | |
PROTECT-HBR, NCT04416581: Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy |
|
|
| Recruiting | 4 | 3100 | RoW | PPI, P-CAB 50 | Duk-Woo Park, MD | Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction | 09/26 | 12/27 | | |
NCT05638867: NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI |
|
|
| Recruiting | 4 | 3944 | RoW | Aspirin + Clopidogrel + Rivaroxaban, Triple Antithrombotic Therapy, Aspirin + Clopidogrel, Dual Antiplatelet Therapy | China National Center for Cardiovascular Diseases | Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome | 12/26 | 01/27 | | |
| Recruiting | 4 | 2000 | Europe | 30-day DAPT, Guideline-directed therapy | St. Antonius Hospital, Daiichi Sankyo, Inc. | Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation, Atrial Flutter, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI, Bleeding, Stroke, Stent Thrombosis, Embolism, Coronary Artery Disease | 10/27 | 12/27 | | |
| Recruiting | 4 | 9930 | RoW | Clopidogrel treatment group, No antiplatelet or anticoagulant group | Seoul National University Hospital, Hallym University Kangnam Sacred Heart Hospital, Hallym University Medical Center, Hanyang University, Keimyung University Dongsan Medical Center, Kangbuk Samsung Hospital, Wonju Severance Christian Hospital | Coronary Artery Disease | 03/30 | 03/30 | | |
